News & Press: Latest News

MDMA Response to President Trump’s State of the Union Address

Tuesday, February 5, 2019  
Share |

MDMA Response to President Trump’s

State of the Union Address


Washington, D.C. – Mark Leahey, President and CEO of the Medical Device Manufacturers Association (MDMA), issued the following statement in response to President Trump’s State of the Union Address:


“MDMA couldn’t agree more with President Trump that it is critical for Congress to work in a bipartisan manner to enact policies that benefit patients, the health care ecosystem and the economy, and there is no better example than the ongoing work to repeal the medical device tax.


“Since 2009, MDMA and a growing coalition of innovators, providers, patient groups and more have worked with policy makers to fully and permanently end this tax that stifles innovation, and thwarts investments into the cures and therapies of tomorrow.  This is why just last year the House of Representatives voted to repeal the device tax with a historic bipartisan level of support.


“If Congress does not act this year, this tax on innovation will once again divert billions of dollars away from investments in high tech manufacturing and research and development across the United States.  We cannot let this happen, and MDMA is committed to working with the overwhelming bipartisan majority in Congress that agrees with us.


“In addition, medical technology innovators will continue to answer the call for reducing health care costs and addressing challenges like the opioid epidemic.  This dynamic industry has a proud tradition of developing life-saving and life-changing products that reduce hospital stays, improve outcomes and increase the standard of living so people can live healthier, more productive lives.  In order for this trend to continue, it is important to have the proper regulatory and reimbursement frameworks in place to support an environment where solutions to the ongoing needs facing patient care can be provided.  


“The United States continues to lead the world in medical technology manufacturing, but we cannot take this for granted.  MDMA remains laser-focused on working with all policymakers and stakeholders who agree that it is important to protect our leadership position in this dynamic field.  At the end of the day, patients and physicians benefit the most when medical innovation is allowed to flourish.”